WEI HU to Antineoplastic Agents
This is a "connection" page, showing publications WEI HU has written about Antineoplastic Agents.
Connection Strength
0.341
-
Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov. 2008 Nov; 3(3):162-77.
Score: 0.067
-
Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003 Dec; 4(12):721-9.
Score: 0.047
-
Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int J Gynecol Cancer. 2002 Mar-Apr; 12(2):202-7.
Score: 0.042
-
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
Score: 0.023
-
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb; 200(2):177.e1-9.
Score: 0.017
-
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res. 2008 Oct; 25(10):2272-82.
Score: 0.016
-
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug; 17(4):739-63.
Score: 0.015
-
Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32.
Score: 0.014
-
Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006 Jun; 6(4):333-63.
Score: 0.014
-
Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol. 2004 Jul; 130(7):423-8.
Score: 0.012
-
Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol. 2004 Apr; 93(1):149-54.
Score: 0.012
-
Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):701-34.
Score: 0.012
-
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol. 2003 Oct; 129(10):549-55.
Score: 0.012
-
Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin Cancer Res. 1998 Jun; 4(6):1383-91.
Score: 0.008
-
DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1997 Oct; 6(10):849-55.
Score: 0.008
-
Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50.
Score: 0.006
-
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.
Score: 0.006
-
Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008 Sep; 110(3 Suppl 2):S67-71.
Score: 0.004
-
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res. 2003 Mar; 9(3):1161-70.
Score: 0.003
-
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol. 2002 Aug; 118(2):521-34.
Score: 0.003